NON-SPHERICAL CONTRAST AGENTS FOR CEST MRI BASED ON BULK MAGNETIC SUSCEPTIBILITY EFFECT
    1.
    发明申请
    NON-SPHERICAL CONTRAST AGENTS FOR CEST MRI BASED ON BULK MAGNETIC SUSCEPTIBILITY EFFECT 审中-公开
    非球形对比剂基于大块磁性可靠性影响的CEST MRI

    公开(公告)号:US20100254913A1

    公开(公告)日:2010-10-07

    申请号:US12744494

    申请日:2008-11-21

    IPC分类号: A61K49/10 A61K49/06

    CPC分类号: A61K49/1812 A61K49/1815

    摘要: In magnetic resonance imaging (MRI) based on chemical exchange-dependent saturation transfer (CEST), a novel carrier for CEST contrast agents is provided. The carrier is non-spherical and comprises a semipermeable shell, wherein the shell comprises a paramagnetic compound. The shell encloses a cavitycomprising an MR analyte, wherein the semipermeable shell allows diffusion of the MR analyte. The CEST effect is based on the 5 bulk magnetic susceptibility effect caused by the anisotropy of the carrier. This leads to a versatile carrier that does not require interaction of the analyte with a paramgnetic chemical shift reagent.

    摘要翻译: 在基于化学交换依赖性饱和转移(CEST)的磁共振成像(MRI)中,提供了一种用于CEST造影剂的新载体。 载体是非球形的并且包含半透性壳,其中壳包含顺磁性化合物。 壳体包围一个包含MR分析物的空腔,其中半透膜允许MR分析物的扩散。 CEST效应基于由载体的各向异性引起的5体积磁化率效应。 这导致通用载体,其不需要分析物与辅助化学位移试剂的相互作用。

    MR IMAGING WITH CEST CONTRAST ENHANCEMENT
    2.
    发明申请
    MR IMAGING WITH CEST CONTRAST ENHANCEMENT 审中-公开
    成像与CEST对比增强

    公开(公告)号:US20110288402A1

    公开(公告)日:2011-11-24

    申请号:US13139518

    申请日:2009-12-15

    IPC分类号: A61B5/055

    CPC分类号: G01R33/5601 G01R33/5616

    摘要: The invention relates to a method of MR imaging of at least a portion of a body of a patient placed in an examination volume of an MR device. The object of the invention is to improve CEST contrast enhanced imaging. The method of the invention comprises the following steps: a) saturation of nuclear magnetization of exchangeable protons of a CEST contrast agent administered to the patient by subjecting the portion of the body to at least one frequency-selective saturation RF pulse matched to the MR frequency of exchangeable protons of the CEST contrast agent, wherein the saturation period, i.e. the duration of the frequency-selective saturation RF pulse, is shorter than the time required for saturation to build up a full CEST contrast enhancement effect when starting from zero saturation; b) generating at least one MR signal of water protons of the body by subjecting the portion of the body to an MR imaging sequence comprising at least one RF pulse and switched magnetic field gradients; c) acquiring sampling the at least one MR signal from the body; d) repeating steps a) to c) a number of times under variation of parameters of the MR imaging sequence, wherein MR signals are acquired and sampled during a saturation build-up period, i.e. before a steady state of the CEST effect is achieved; e) reconstructing a proton-density weighted, CEST contrast-enhanced MR image from the acquired and sampled MR signals.

    摘要翻译: 本发明涉及放置在MR装置检查体积中的患者身体的至少一部分的MR成像方法。 本发明的目的是改善CEST对比度增强成像。 本发明的方法包括以下步骤:a)通过使身体的一部分经受与MR频率匹配的至少一个频率选择性饱和RF脉冲,使给予患者的CEST造影剂的可交换质子的核磁化饱和 的CEST造影剂的可交换质子,其中饱和周期,即频率选择性饱和RF脉冲的持续时间比从零饱和开始时建立饱和CEST对比度增强效果所需的时间短; b)通过使身体的一部分经受包括至少一个RF脉冲和切换的磁场梯度的MR成像序列来产生身体的水质子的至少一个MR信号; c)从身体采集至少一个MR信号; d)在MR成像序列的参数变化下重复步骤a)至c)多次,其中在饱和建立期间,即在实现CEST效应的稳定状态之前获取和采样MR信号; e)从获取和采样的MR信号重构质子密度加权的CEST对比度增强的MR图像。

    DRUG CARRIER PROVIDING MRI CONTRAST ENHANCEMENT
    5.
    发明申请
    DRUG CARRIER PROVIDING MRI CONTRAST ENHANCEMENT 有权
    药物载体提供MRI对比增强

    公开(公告)号:US20110177009A1

    公开(公告)日:2011-07-21

    申请号:US13062550

    申请日:2009-09-03

    摘要: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.

    摘要翻译: 描述了可用于磁共振成像(MRI)指导的药物释放的药物载体,其包含能够释放作为局部刺激的结果的封闭的生物活性剂的壳,例如, 能量输入,例如热量,其中壳体包围19F MR造影剂。 优选地,基于化学交换依赖性饱和转移(CEST)的原理,载体也用作MRI的对比度增强剂。 为此,壳体包围包含顺磁化学位移试剂,质子分析物池和19F造影剂的空腔,并且其中壳允许质子分析物的扩散。

    STIMULI-RESPONSIVE CARRIERS FOR MPI-GUIDED DRUG DELIVERY
    6.
    发明申请
    STIMULI-RESPONSIVE CARRIERS FOR MPI-GUIDED DRUG DELIVERY 审中-公开
    用于MPI指导药物递送的STIMULI-RESPONSIVE CARRIERS

    公开(公告)号:US20120100079A1

    公开(公告)日:2012-04-26

    申请号:US13379056

    申请日:2010-06-25

    IPC分类号: A61K49/18 A61P41/00

    CPC分类号: A61K9/0009

    摘要: The present invention relates to a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent; wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus and wherein said contrast agent comprises magnetic particles which are capable of being detected by Magnetic Particle Imaging (MPI), wherein at least more than 5% (w/w) of the magnetic particles comprised in said contrast agent have a magnetic moment of at least −18 m 2 A, 10 wherein said magnetic particles are preferably composed of Fe, Co, Ni, Zn or Mn or alloys thereof or oxides of any of these. The present invention further relates to the use of such a composition or a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent, wherein said contrast agent is capable of being detected by MPI and wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus as a carrier for a controlled delivery of a drug, as well as to a method of data acquisition for the control of a drug delivery process comprising the detection or localization via MPI of such compositions. In a further aspect the present invention relates to such compositions for treating a pathological condition, wherein the treatment comprises the release of the drug by the application of a stimulus.

    摘要翻译: 本发明涉及包含形成空腔的壳结构的组合物,其中所述壳结构包含药物,并且其中所述组合物与至少一种造影剂相关联; 其中所述壳结构能够在施加外部刺激时将其内容物释放到外部,并且其中所述造影剂包括能够通过磁性粒子成像(MPI)检测的磁性颗粒,其中至少大于5% w / w)包含在所述造影剂中的磁性颗粒具有至少-18m 2 A,10的磁矩,其中所述磁性颗粒优选由Fe,Co,Ni,Zn或Mn组成或其合金或其合金或 任何这些。 本发明还涉及这样的组合物或组合物在组合物中的用途,所述组合物或组合物包含形成空腔的壳结构,其中所述壳结构包含药物,并且其中所述组合物与至少一种造影剂缔合,其中所述造影剂能够 被MPI检测到,并且其中所述外壳结构能够在外部刺激作为用于控制药物递送的载体的情况下将其内容释放到外部,以及用于控制药物的数据采集方法 药物递送过程包括通过这种组合物的MPI的检测或定位。 在另一方面,本发明涉及用于治疗病理状况的这种组合物,其中所述治疗包括通过施用刺激物释放药物。

    Process for the production of a polyolefin-based composite material of high rigidity

    公开(公告)号:US06583200B2

    公开(公告)日:2003-06-24

    申请号:US10050040

    申请日:2002-01-17

    IPC分类号: C08K900

    CPC分类号: C08K9/04 C08L23/02

    摘要: A process for production of a polyolefin-based composite material of high rigidity, containing a polyolefin and a layered clay, involves impregnating a layered, swellable clay which is interstratified with a tetraalkyl cation, with at least one polymerizable monomer and then mixing this impregnated clay with a polyolefin and a peroxide, at a temperature above the melting point of the polyolefin. A polyolefin-based composite material containing 98-50 wt. % of a polyolefin, 1-50 wt. % of another homo- or copolymer and 1-50 wt. % of a layered clay, wherein the ratio between the modulus of elasticity of the material and that of the initial polyolefin, at a temperature which is 30° C. below the melting temperature of the polyolefin, is higher than or equal to 1 has high rigidity.